Search the Newsreel

Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD

Empowered Funds LLC has made a new investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), acquiring 48,982 shares valued at approximately $1.09 million. This comes as institutional investors hold 96.71% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average price target …

Mirum Pharmaceuticals (MIRM) Losses Put Its Valuation Narrative Back In Focus

Mirum Pharmaceuticals (MIRM) reported wider net losses in Q2 and H1 2026, yet its share price has seen significant gains, up 28.91% year-to-date and 50.93% over one year. The company is currently trading at approximately $100, which analysts suggest is 30.2% undervalued with a …

239,800 Shares in Keurig Dr Pepper, Inc $KDP Purchased by Alberta Investment Management Corp

Alberta Investment Management Corp recently acquired a new stake of 239,800 shares in Keurig Dr Pepper, Inc. (NASDAQ:KDP), valued at approximately $7.85 million. This purchase is part of broader institutional investment activity, with several other hedge funds also adjusting their positions in KDP. Analyst …

AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

AMG National Trust Bank has made a new $1.22 million investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by purchasing 1,956 shares. This investment comes amidst various other hedge funds adjusting their positions in the biopharmaceutical company, which recently reported strong quarterly earnings, beating analyst estimates, …

113,200 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Alberta Investment Management Corp

AMG National Trust Bank Purchases Shares of 15,584 Marathon Petroleum Corporation $MPC

AMG National Trust Bank has acquired 15,584 shares of Marathon Petroleum Corporation (MPC) in the second quarter, valued at approximately $3.98 million. This move is part of broader institutional interest, with several other hedge funds also adjusting their stakes in the oil and gas …

1ST Source Bank Takes $1.10 Million Position in Marathon Petroleum Corporation $MPC

1ST Source Bank has acquired a $1.10 million stake in Marathon Petroleum (MPC) by purchasing 4,299 shares in the second quarter. Other institutional investors have also significantly increased their holdings in the company. Marathon Petroleum reported strong Q2 earnings, beating analyst estimates, and has …

Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA

Assenagon Asset Management S.A. significantly reduced its stake in Protara Therapeutics (NASDAQ:TARA) by 89.4% in the second quarter, selling 507,667 shares and retaining 59,954 shares valued at $229,000. Despite this, other institutional investors like Geode Capital Management increased their positions, with overall institutional ownership …

Kotak's Mid-Cap Model Portfolio: Eureka Forbes, ICICI Pru Life Lead With Highest Upside — Check Target Prices

Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE

2,486,038 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by AIGH Capital Management LLC

AIGH Capital Management LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 2,486,038 shares valued at approximately $26.7 million in the second quarter, making it their 9th largest holding. Other institutional investors like Norges Bank and Bank of New York Mellon Corp …

SENORES PHARMACEUTICALS L Share Price: 52-Week High Analysis

TSX:MDNA Jumps 15%: What Is Driving Medicenna Therapeutics Stock Higher?

What is HC Wainwright's Forecast for DWTX FY2029 Earnings?

HC Wainwright Issues Pessimistic Forecast for IPSC Earnings

HC Wainwright has lowered its Q3 2026 EPS forecast for Century Therapeutics (NASDAQ:IPSC) to a loss of $0.12 per share, down from a previous estimate of $0.11, while maintaining a "Buy" rating and a $5.00 price target. This revision follows Century Therapeutics reporting a …

Research Analysts Set Expectations for CADL Q3 Earnings

HC Wainwright has lowered its Q3 2026 EPS forecast for Candel Therapeutics (NASDAQ:CADL) to a loss of $0.35 per share, though it maintained a "Buy" rating and a $23 price target. This adjustment follows Candel Therapeutics missing its Q2 earnings consensus, reporting a loss …

What is HC Wainwright's Forecast for BCRX Q3 Earnings?

Noble Financial Has Positive Forecast for UNCY Q3 Earnings

HC Wainwright Issues Pessimistic Forecast for TRAX Earnings

Research Analysts Set Expectations for UNCY Q3 Earnings

Euro Manganese Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

Q3 EPS Estimate for Cardiol Therapeutics Raised by Analyst

Anheuser-Busch InBev stock draws support from volume growth

Anheuser-Busch InBev (BUD) stock is gaining support following a 1.1% increase in beer volumes during the second quarter of 2026. Analysts have raised fiscal year 2026 EPS estimates to $4.43, indicating improved earnings expectations. Despite a slight dip in regular trading, the stock showed …

Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for Inovio Pharmaceuticals (NASDAQ:INO) to a loss of $0.20 per share, up from a previous estimate of $0.24, while maintaining a "Neutral" rating. Analyst sentiment for Inovio is generally positive, with a consensus "Moderate Buy" …

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen has upgraded Rocket Pharmaceuticals (NASDAQ:RCKT) from a "sell" to a "hold" rating, aligning with the broader analyst consensus and an average target price of $8.57. The company's shares opened at $3.47 and have seen significant insider selling totaling $327,220 over the …

Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M

* Citius Pharmaceuticals press release [https://seekingalpha.com/pr/20620155-citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides] (CTXR [https://seekingalpha.com/symbol/CTXR]): Q3 GAAP EPS of -$0.34 misses by $0.09. * Revenue of $1.5M misses by $8.27M. * Cash and cash equivalents of $17.0 million as of June 30, 2026. MORE ON CITIUS PHARMACEUTICALS * Seeking Alpha’s Quant …

BioXcel Therapeutics earnings missed by $0.07, revenue fell short of estimates

BioXcel Therapeutics (NASDAQ: BTAI) reported a second-quarter EPS of $-0.490, missing the analyst estimate by $0.07. Revenue for the quarter was $182K, falling short of the consensus estimate of $403.32K. The company's stock price has shown a 9.170% increase in the last three months …

Why Marathon Petroleum (MPC) Is Getting Attention Today

Verändern der Umsatzsprung und der Gewinnrückgang im zweiten Quartal die optimistischen Aussichten für Keurig Dr Pepper (KDP)?

Ligand Pharmaceuticals (LGND) Could Be 9% Undervalued As Earnings And Guidance Hold

Does Q2’s Revenue Jump And Profit Dip Reframe The Bull Case For Keurig Dr Pepper (KDP)?

ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks

This article lists numerous ETFs that invest in Arrowhead Pharmaceuticals, Inc. stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price change, relative volume, and 3-year NAV total return. The ETFs cover a range of investment strategies including …

CAPR INVESTOR ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before September 28, 2026 Deadline

Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for purchasers of its securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to the statistical analysis …

Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap?

BIOMARIN PHARMACEUTICAL INC. : PIPER SANDLER RAISES TARGET PRICE TO $88 FROM $82

Piper Sandler has increased its target price for BioMarin Pharmaceutical Inc. (BMRN.O) from $82 to $88. This adjustment reflects an updated outlook from the analytical firm regarding the biotechnology company's valuation. The news was reported by Reuters.

Valeura Energy: Low Debt, Healthy Oil Pricing